The compounded vs brand decision in 90 seconds

I had three different friends in three different cities ask me some version of this question last week. The fastest version of the answer is also the most useful one.

In May 2026, the compounded vs brand decision is mostly about what you want from your supply chain.

If you want the cheapest legal route and you're willing to absorb the risk that your provider has to pivot away from compounded supply within the next year, compounded telehealth (Mochi, Henry Meds, Eden, the smaller players) is real. It works. The medication is the same molecule. You're paying $99 to $250 a month instead of $1000+ for brand cash. The trade-off is structural, not pharmacological.

The structural risk has three pieces. The April 30 FDA proposal to exclude tirzepatide from the 503B bulks list is going to land sometime in Q3 2026. When it does, every compounded telehealth operator has to either pivot to brand pharmacy (more expensive for the patient), pivot to a different molecule (oral options, smaller-volume specialty drugs), or scale down. Some have already announced their pivot. Some haven't. The ones that haven't are likely to handle the transition messier than the ones that have.

If you want supply you can rely on for the next 18 months without worrying about regulatory weather, brand pharmacy is the answer. Mounjaro and Zepbound through your insurance, or through LillyDirect's reduced-cash program, or through one of the brand-only telehealth operators (Ro, Calibrate, WW Clinic). The price tag is bigger if you don't have insurance. The reliability is real.

If you have insurance and you've never run a prior auth for these drugs, run one this week. Most commercial plans cover at least one of the brand GLP-1s now. The PA paperwork takes an hour of your prescriber's time. The savings can be enormous. Patients who skip the prior auth and pay cash for compounded are often skipping a $25 monthly copay they could have had. Don't be that patient.

If you don't have insurance and you don't qualify for any of the cash-pay programs, the math gets harder. The honest answer is that compounded telehealth is what most of those patients are using, and the better operators (Ro especially, which has already pivoted to brand-only with cash-pay Foundayo at $149/month) are reasonable alternatives. The thinly capitalized ones are the ones that worry me.

What I would not do, even on a tight budget: research-chemical tirzepatide ordered online. The grey market quality distribution is not something I'd bet my body on, and the customs enforcement environment is tightening in 2026. The savings are real, the downside is the kind you don't want to find out about.

That's the whole frame, in 90 seconds. Decide what you want from your supply chain. The medication is the same. The structure around it is the question.

If you want the longer version with vendor scorecards and per-region pricing, the buyer's guide at /blog/compounded-vs-brand-tirzepatide goes deeper. But this is the answer most people actually need.